| Size | Price | |
|---|---|---|
| 500mg | ||
| 1g | ||
| Other Sizes |
| Targets |
The primary target is the Kv1.5 potassium channel (KCNA5), which carries the ultra-rapid delayed rectifier potassium current (IKur) in atrial myocytes. DDO-02005 free base inhibits Kv1.5 with an IC50 of 0.72 μM. Kv1.5 inhibition prolongs atrial action potential duration and refractoriness, which is the basis for its anti-AF activity.
|
|---|---|
| ln Vitro |
In vitro, DDO-02005 free base inhibits Kv1.5 current with an IC50 of 0.72 μM in patch-clamp electrophysiology. It shows antiarrhythmic activity against aconitine-induced arrhythmias in vivo. Specific cellular EC50 values for action potential prolongation are not uniformly disclosed.
|
| ln Vivo |
In vivo, DDO-02005 free base shows good anti-AF effects in a CaCl2-ACh-induced AF rat model and effective antiarrhythmic activity against aconitine-induced arrhythmias. Doses and full pharmacokinetic parameters are not uniformly disclosed, but the compound demonstrates efficacy in rodent arrhythmia models.
|
| Enzyme Assay |
Kv1.5 inhibition is measured by whole-cell patch-clamp electrophysiology in cells expressing Kv1.5. The compound is applied at serial concentrations, and the peak or steady-state current is measured. IC50 is derived from dose–response curves; the disclosed IC50 is 0.72 μM. The assay includes a reference Kv1.5 blocker (e.g., 4-AP) as a positive control.
|
| Cell Assay |
Cellular assays use atrial myocytes or Kv1.5-expressing cell lines. Action potential duration is measured by current-clamp electrophysiology. IKur current is recorded by voltage-clamp. Atrial fibrillation inducibility can be assessed in isolated atrial preparations. Cytotoxicity is measured by MTT in non-cardiac cells.
|
| Animal Protocol |
In vivo anti-AF efficacy is tested in rats. AF is induced by CaCl2-ACh or aconitine, and the compound is administered intravenously or orally at doses selected from a pilot tolerability study. Duration of AF, atrial effective refractory period, and arrhythmia score are primary endpoints. ECG is monitored continuously.
|
| References |
| Molecular Formula |
C21H25N3O2
|
|---|---|
| Molecular Weight |
351.44
|
| Exact Mass |
351.194
|
| CAS # |
1186134-30-4
|
| Related CAS # |
DDO-02005;1186049-44-4
|
| PubChem CID |
44188607
|
| Appearance |
Typically exists as solid at room temperature
|
| LogP |
3.2
|
| tPSA |
50.5
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
26
|
| Complexity |
420
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
COC1=CC=C(C=C1)CNC2CCN(CC2)CC3=NC4=CC=CC=C4O3
|
| InChi Key |
OQLSBAGRFBHBFL-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C21H25N3O2/c1-25-18-8-6-16(7-9-18)14-22-17-10-12-24(13-11-17)15-21-23-19-4-2-3-5-20(19)26-21/h2-9,17,22H,10-15H2,1H3
|
| Chemical Name |
1-(1,3-benzoxazol-2-ylmethyl)-N-[(4-methoxyphenyl)methyl]piperidin-4-amine
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80: Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 :Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400  (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.8454 mL | 14.2272 mL | 28.4544 mL | |
| 5 mM | 0.5691 mL | 2.8454 mL | 5.6909 mL | |
| 10 mM | 0.2845 mL | 1.4227 mL | 2.8454 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.